Systematic Reviews
Copyright ©The Author(s) 2024.
World J Crit Care Med. Mar 9, 2024; 13(1): 89026
Published online Mar 9, 2024. doi: 10.5492/wjccm.v13.i1.89026
Table 1 Consensus statement and summary of overall agreement
Questions
Responses, n = 11 (%)
Consensus status - overall agreement
Agreed/yes (%)
Disagreed/no (%)
Q1. Is there a need for adjuvant therapy in the management of refractory septic shock patients, when standard of care is insufficient?10 (90.91)1 (9.09)A total of 90.91% experts agreed on the need for adjuvant therapy in the management of refractory septic shock patients, when the standard of care is insufficient. (Consensus Achieved)
Q2. In case of refractory septic shock cycle, CytoSorb® ideally be initiated within a maximum of 24 h after diagnosis and start of standard therapy11 (100)0 (0)All experts (100%) agreed that in refractory septic shock cycle, CytoSorb® ideally be initiated within a maximum of 24 h after diagnosis and start of standard therapy. (Consensus Achieved)
Q3. IL-6 levels are not a mandatory parameter to decide on using CytoSorb® therapy in refractory septic shock patients10 (90.91)1 (9.09)A total of 90.91% experts agreed that IL-6 levels are not a mandatory parameter to decide on using CytoSorb® therapy in refractory septic shock patients. (Consensus Achieved)
Q4. There are patients who may require more than one CytoSorb® adsorber to achieve sufficient haemodynamic stabilization10 (90.91)1 (9.09)A total of 90.91% experts agreed that there are patients who may require more than one CytoSorb® adsorber to achieve sufficient haemodynamic stabilization. (Consensus Achieved)
Q5. If you want to continue with CytoSorb® therapy, the absorber should be changed after 6-24 h depending on the clinical course and the machine type availability11 (100)0 (0)All experts (100%) agreed that if CytoSorb® therapy is continued, the absorber should be changed after 6-24 h depending on the clinical course and the machine type availability. (Consensus Achieved)
Q6. CytoSorb® therapy is generally a safe therapy10 (90.91)1 (9.09)A total of 90.91% experts agreed that CytoSorb® is generally a safe therapy. (Consensus Achieved)
Q7. Sepsis-induced AKI requiring RRT is no prerequisite to initiate CytoSorb® therapy in refractory septic shock patients11 (100)0 (0)All experts (100%) agreed that sepsis-induced AKI requiring RRT is not a prerequisite to initiate CytoSorb® therapy in refractory septic shock patients. (Consensus Achieved)
Q8. Evaluation of the efficacy of CytoSorb® therapy should be based on more proximal endpoints like haemodynamic stabilization, inflammatory biomarkers, and/or improvement in the organ function instead of mortality10 (90.91)1 (9.09)A total of 90. 91% experts agreed that the evaluation of the efficacy of CytoSorb® therapy should be based on endpoints like haemodynamic stabilization, inflammatory biomarkers, and/or improvement in the organ function instead of mortality. (Consensus Achieved)
Q9. Do you think this flowchart can be helpful to a doctor very new to the therapy to ensure a certain level of best practice?11 (100)0 (0)All experts (100%) agreed on the (revised) flowchart for doctor who are new to the therapy to ensure a certain level of best practice. (Consensus Achieved)
Table 2 Summary of consensus statements
Number
Summary of consensus statements
1There is the need for adjuvant therapy (CytoSorb® haemoadsorption) in the management of refractory septic shock patients, when the standard of care is insufficient
2In refractory septic shock cycle, CytoSorb® ideally be initiated within a maximum of 24 h after diagnosis and start of standard therapy
3In the initiation of CytoSorb® therapy in refractory septic shock patient, IL-6 levels are not a pre-requisite or mandatory parameter for decision making
4In a subset of patients, more than one CytoSorb® adsorber may be required to achieve sufficient haemodynamic stabilization
5In continuation of CytoSorb® therapy, the absorber should be changed after 6-24 h depending on the clinical course and the machine type availability
6CytoSorb® therapy is generally a safe therapy
7Sepsis-induced AKI requiring RRT is not a prerequisite to initiate CytoSorb® therapy in refractory septic shock patients
8The evaluation of the efficacy of CytoSorb® therapy should be based on endpoints like haemodynamic stabilization, inflammatory biomarkers, and/or improvement in the organ function, instead of mortality
9The (displayed, Figure 2) flowchart can be helpful to a doctor very new to the therapy to ensure a certain level of best practice